Literature DB >> 9413949

Multiple simultaneous gastric carcinomas.

C Wittekind1, M Klimpfinger, P Hermanek, A Tannapfel.   

Abstract

A total of 1664 patients with gastric cancer were examined to evaluate the rate of multiple synchronous primary tumours. In cases of multiple synchronous cancer (MSC), the tumours were analysed immunohistochemically for their expression pattern of p53, c-erbB2, ras, E-cadherin and proliferative activity. Multiple synchronous gastric carcinomas (MSCs) were observed in 61 out of 1664 patients (3.7%), with a total of 134 carcinomas. In our series, early carcinoma was observed more frequently in MSC than in solitary cancers. The comparison of tumour stage in MSC and solitary tumours revealed that multiple early gastric cancers were significantly more often of type I (protruded type) and IIa (superficial elevated type) than solitary early cancer. Multiple advanced carcinomas were more often of a lower pT category than solitary advanced gastric cancer. Performing immunohistochemistry for p53, c-erbB2 and ras in 134 tumours with MSCs, we observed positivity rates of 33%, 59% and 87% respectively. In 43 patients, the multiple tumours in each individual patient demonstrated an identical status of p53 and c-erbB2, and in 42 patients a similar pattern of E-cadherin expression was observed. The proliferative index, determined by proliferating cell nuclear antigen (PCNA) immunolabelling, did not differ significantly between the MSC in each patient. Ras immunostaining was detected in 53 out of 61 patients, but also in metaplasia and regenerative hyperplasia in the specimens. In survival analysis, no difference was observed between patients with solitary or multiple early or advanced carcinomas. Our results suggest that in at least a high proportion of patients with gastric cancer multiple primary tumours arise from precancerous conditions leading to similar genetic alterations.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9413949      PMCID: PMC2228195          DOI: 10.1038/bjc.1997.604

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  24 in total

Review 1.  Review: assessment of cell proliferation in histological material.

Authors:  P A Hall; D A Levison
Journal:  J Clin Pathol       Date:  1990-03       Impact factor: 3.411

2.  Expression of c-erbB-2 oncoprotein in gastric carcinoma. Immunoreactivity for c-erbB-2 protein is an independent indicator of poor short-term prognosis in patients with gastric carcinoma.

Authors:  Y Yonemura; I Ninomiya; S Ohoyama; H Kimura; A Yamaguchi; S Fushida; T Kosaka; K Miwa; I Miyazaki; Y Endou
Journal:  Cancer       Date:  1991-06-01       Impact factor: 6.860

Review 3.  Molecular biology and gastric carcinoma.

Authors:  P A Wright; G T Williams
Journal:  Gut       Date:  1993-02       Impact factor: 23.059

4.  p53 alteration in gastric precancerous lesions.

Authors:  Y H Shiao; M Rugge; P Correa; H P Lehmann; W D Scheer
Journal:  Am J Pathol       Date:  1994-03       Impact factor: 4.307

Review 5.  The molecular biology of esophageal and gastric cancer and their precursors: oncogenes, tumor suppressor genes, and growth factors.

Authors:  G Stemmermann; S C Heffelfinger; A Noffsinger; Y Z Hui; M A Miller; C M Fenoglio-Preiser
Journal:  Hum Pathol       Date:  1994-10       Impact factor: 3.466

6.  [Molecular biology and immunohistochemical studies of Her2/neu oncogene in stomach cancer].

Authors:  J Jähne; C Urmacher; A Albino; H J Meyer; R Pichlmayr
Journal:  Chirurg       Date:  1994-04       Impact factor: 0.955

7.  Incidence, diagnosis and significance of multiple gastric cancer.

Authors:  Y Kodera; Y Yamamura; A Torii; K Uesaka; T Hirai; K Yasui; T Morimoto; T Kato; T Kito
Journal:  Br J Surg       Date:  1995-11       Impact factor: 6.939

8.  Frequent co-occurrence of mutator phenotype in synchronous, independent multiple cancers of the stomach.

Authors:  K Shinmura; H Sugimura; Y Naito; P G Shields; I Kino
Journal:  Carcinogenesis       Date:  1995-12       Impact factor: 4.944

9.  Multiple primary gastric and colorectal cancer in Japan.

Authors:  Y Ikeda; M Mori; K Kajiyama; Y Haraguchi; K Sugimachi
Journal:  Int Surg       Date:  1995 Jan-Mar

10.  Effect of hepatocyte growth factor on the expression of E- and P-cadherin in gastric carcinoma cell lines.

Authors:  A Tannapfel; W Yasui; H Yokozaki; C Wittekind; E Tahara
Journal:  Virchows Arch       Date:  1994       Impact factor: 4.064

View more
  5 in total

1.  Endoscopic Screening for Remnant Gastric Cancer: Points to be Considered.

Authors:  Jung Ho Park; Jun Haeng Lee; Poong-Lyul Rhee; Jae J Kim; Jong Chul Rhee; Sung Kim; Cheol Keun Park
Journal:  Gut Liver       Date:  2007-06-30       Impact factor: 4.519

Review 2.  Intestinal metaplasia and anastomotic recurrence of gastric carcinoma.

Authors:  Elroy Patrick Weledji; George Enow Orock; Marcelin Ngowe Ngowe
Journal:  J Gastrointest Oncol       Date:  2014-12

3.  Expression of p53, c-erbB-2 and Ki67 in intestinal metaplasia and gastric carcinoma.

Authors:  Yao Zheng; Lin Wang; Jian-Ping Zhang; Jing-Yan Yang; Zhu-Mei Zhao; Xiao-Ying Zhang
Journal:  World J Gastroenterol       Date:  2010-01-21       Impact factor: 5.742

4.  Clinicopathologic and immunohistochemistry characterization of synchronous multiple primary gastric adenocarcinoma.

Authors:  Ulysses Ribeiro; Uana M Jorge; Adriana V Safatle-Ribeiro; Osmar K Yagi; Cristovam Scapulatempo; Rodrigo O Perez; Carlos E P Corbett; Venâncio A F Alves; Bruno Zilberstein; Joaquim Gama-Rodrigues
Journal:  J Gastrointest Surg       Date:  2007-03       Impact factor: 3.267

5.  Genetic and epigenetic markers to identify high risk patients for multiple early gastric cancers after treatment with endoscopic mucosal resection.

Authors:  Mayumi Fukuda; Hiroshi Yokozaki; Masatsugu Shiba; Kazuhide Higuchi; Tetsuo Arakawa
Journal:  J Clin Biochem Nutr       Date:  2007-05       Impact factor: 3.114

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.